Technical
Glycom's principal activity is to develop and sell new biomolecules to the food ingredient industry. The company has unique know-how and abilities within carbohydrate chemistry which it utilizes for the development of industrial scale production of Human Milk Oligosaccharides (HMOs). HMOs are high value ingredients in infant formula and potentially other functional food products. Glycom is presently developing, in its own laboratories, synthetic processes for the preparation of selected HMOs which are suitable for multi-ton scale production.
Value Proposition
HMOs are not found in cow milk and therefore currently not available in infant formulas. HMOs are documented to have prebiotic effects (nutrition for healthy intestinal bacteria) and to have important antibacterial/antiviral effects as well as stimulating early brain development on infants. Glycoms ability to synteticly produce HMO at a reasonable price will allow producers of in particular infant formula to offer their products with HMO.
Glycom has a long-term cooperation agreement and partnership with Nestlé Nutrition and has initiated a second wave of HMO development and pre-industrialization in the beginning of 2010.
Additional information